Geode Capital Management’s Hepion Pharmaceuticals HEPA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-904
| Closed | -$21.2K | – | 4493 |
|
|
2024
Q4 | $21.2K | Sell |
904
-37
| -4% | -$1.16K | ﹤0.01% | 4378 |
|
|
2024
Q3 | $31.5K | Buy |
941
+50
| +6% | +$1.98K | ﹤0.01% | 4347 |
|
|
2024
Q2 | $48.1K | Buy |
891
+114
| +15% | +$8.41K | ﹤0.01% | 4291 |
|
|
2024
Q1 | $96.7K | Buy |
777
+79
| +11% | +$9.08K | ﹤0.01% | 4166 |
|
|
2023
Q4 | $114K | Hold |
698
| – | – | ﹤0.01% | 4145 |
|
|
2023
Q3 | $174K | Hold |
698
| – | – | ﹤0.01% | 4038 |
|
|
2023
Q2 | $366K | Buy |
698
+42
| +6% | +$25.8K | ﹤0.01% | 3761 |
|
|
2023
Q1 | $510K | Hold |
656
| – | – | ﹤0.01% | 3642 |
|
|
2022
Q4 | $197K | Sell |
656
-2
| -0.3% | -$845 | ﹤0.01% | 4113 |
|
|
2022
Q3 | $332K | Hold |
658
| – | – | ﹤0.01% | 3938 |
|
|
2022
Q2 | $376K | Hold |
658
| – | – | ﹤0.01% | 3914 |
|
|
2022
Q1 | $848K | Hold |
658
| – | – | ﹤0.01% | 3692 |
|
|
2021
Q4 | $750K | Hold |
658
| – | – | ﹤0.01% | 3849 |
|
|
2021
Q3 | $1.01M | Buy |
658
+7
| +1% | +$11.2K | ﹤0.01% | 3672 |
|
|
2021
Q2 | $1.29M | Buy |
651
+62
| +11% | +$113K | ﹤0.01% | 3477 |
|
|
2021
Q1 | $1.08M | Buy |
589
+386
| +190% | +$846K | ﹤0.01% | 3518 |
|
|
2020
Q4 | $443K | Buy |
203
+187
| +1,169% | +$485K | ﹤0.01% | 3624 |
|
|
2020
Q3 | $49K | Buy |
+16
| New | +$57.4K | ﹤0.01% | 4018 |
|
|
2020
Q1 | – | Sell |
-14
| Closed | -$74K | – | 4140 |
|
|
2019
Q4 | $74K | Buy |
+14
| New | +$54.2K | ﹤0.01% | 4025 |
|
|
2019
Q2 | – | Sell |
-1
| Closed | -$14K | – | 4225 |
|
|
2019
Q1 | $14K | Hold |
1
| – | – | ﹤0.01% | 4112 |
|
|
2018
Q4 | $17K | Hold |
1
| – | – | ﹤0.01% | 4098 |
|
|
2018
Q3 | $35K | Hold |
1
| – | – | ﹤0.01% | 4057 |
|
|
2018
Q2 | $81K | Hold |
1
| – | – | ﹤0.01% | 3912 |
|
|
2018
Q1 | $72K | Hold |
1
| – | – | ﹤0.01% | 3903 |
|
|
2017
Q4 | $113K | Hold |
1
| – | – | ﹤0.01% | 3791 |
|
|
2017
Q3 | $180K | Hold |
1
| – | – | ﹤0.01% | 3698 |
|
|
2017
Q2 | $201K | Hold |
1
| – | – | ﹤0.01% | 3682 |
|
|
2017
Q1 | $626K | Hold |
1
| – | – | ﹤0.01% | 3222 |
|
|
2016
Q4 | $416K | Buy |
+1
| New | +$1.01M | ﹤0.01% | 3336 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 3750 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 3751 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 3736 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 3722 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 3764 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 3707 |
|
Other funds holding HEPA
SM
AFM
HF
TRCT
SS
Geode Capital Management's HEPA Position: Q1 2025 in Review
Geode Capital Management sold out of Hepion Pharmaceuticals (HEPA) in Q1 2025, closing a stake of 904 shares — an estimated $21.2K sold.
Geode Capital Management first reported a position in HEPA in Q4 2016 and held it in 29 quarters. The position peaked at $1.29M in Q2 2021. 16 funds tracked by Wall St. Rank hold HEPA as of Q1 2025.
- Geode Capital Management reported no remaining Hepion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
- Geode Capital Management sold 904 Hepion Pharmaceuticals shares in Q1 2025, an estimated $21.2K.
- Geode Capital Management first reported a position in Hepion Pharmaceuticals in Q4 2016 and held it in 29 quarters.
- Geode Capital Management's Hepion Pharmaceuticals position peaked at $1.29M in Q2 2021.
- 16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q1 2025.
Based on Geode Capital Management's 13F filing for Q1 2025, filed 13 May 2025.